Leerink Partners has recently reduced Agios Pharmaceuticals Inc (AGIO) stock to Market Perform rating, as announced on September 27, 2024, according to Finviz. Earlier, on February 8, 2024, Cantor Fitzgerald had initiated the stock to Overweight. Piper Sandler also initiated Overweight rating with a price target of $41. Additionally, Goldman raised Neutral rating on November 17, 2022, with a target price of $32. SVB Leerink analysts, in their report published on July 27, 2022, also raised Outperform rating and set a price target of $33 for Agios Pharmaceuticals Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Agios Pharmaceuticals Inc (AGIO) Stock Trading Recap
On Monday, Agios Pharmaceuticals Inc (AGIO) stock saw a decline, ending the day at $44.43 which represents a decrease of $-1.18 or -2.59% from the prior close of $45.61. The stock opened at $45.61 and touched a low of $44.16 during the day, reaching a high of $46.24. The volume of shares traded was 0.82 million exceeding the average volume of 0.51 million.
AGIO Stock Performance and Moving Averages
In recent trading, Agios Pharmaceuticals Inc (AGIO) stock price has shown some volatility, fluctuating -2.91% over the last five trades and -3.12% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 53.95%, and it has gained 2.42% in the previous three months. Currently, AGIO is trading at -2.64%, -2.76%, and 25.71% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, AGIO, a Healthcare sector stock, is trading -16.62% below its 52-week high but remains 124.45% above its 52-week low. The Average True Range (ATR) (14 days) of 2.48 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Agios Pharmaceuticals Inc’s Profitability and Valuation Ratios
Agios Pharmaceuticals Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -1293.88% and a profit margin of -1165.69%, with a gross margin of 53.95%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Agios Pharmaceuticals Inc’s market capitalization stands at $2.53 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 80.73, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 3.83, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.05% of Agios Pharmaceuticals Inc (AGIO)’s shares, while financial institutions hold 101.60%.
Notable insider trades include Jones Cecilia, Chief Financial Officer at Agios Pharmaceuticals Inc (AGIO), who sold 2542 shares on Sep 26 ’24, at $49.03 each, totaling $0.12 million. On Aug 08 ’24, Goff Brian, Chief Executive Officer, sold 11091 shares for $42.75 each, amounting to $0.47 million. Additionally, on Jul 01 ’24, Gheuens Sarah sold 3705 shares at $43.85 each, generating $0.16 million.
